Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom

Autor:	Wilson, Michele R., Bergman, Annika, Chevrou-Severac, Helene, Selby, Ross, Smyth, Michael, Kerrigan, Matthew C.
Zdroj:	The European Journal of Health Economics, 2018 Mar 01. 19(2), 229-240.
Databáze:	JSTOR Journals
Externí odkaz:	https://www.jstor.org/stable/45155587 Zobrazit plný text záznamu Full text from SpringerLink